New drug cocktail aims to control aggressive blood cancer
NCT ID NCT04430894
Summary
This study is testing a new combination of four drugs for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see how well this weekly treatment regimen controls the cancer and leads to deep remission. About 50 participants will receive the drug combination for an initial 8-month period, followed by up to two years of maintenance therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.